摘要
目的 探讨卵巢癌抗原-125（CA125）的测定对卵巢癌的诊断及预后的临床价值。方法 采用ELISA法测定124例患者治疗前后的血清CA125（卵巢癌19例、子宫肌瘤34例、卵巢良性畸胎瘤29例及其它妇科疾病42例）。结果 卵巢癌阳性率94.7%（18/19），子宫肌瘤、卵巢良性畸胎瘤及其它妇科疾病的阳性率分别为17.6%(6/34)、24%（7/29）和14.35%（6/42）。19例卵巢癌患者经化疗或手术治疗后有14例血清CA125含量显著下降，其余良性妇科疾病经治疗后虽然有不同程度的降低，但降低幅度不大。 结论 血清CA125测定对卵巢癌的诊断及预后有较高的临床价值。
Objective To evaluate the diagnostic and prognostic validity of determination serum CA125 in-patients with ovarian cancer. MethodsTheserum levels of CA125 in 124 patients with gynecologic diseases (including 19 cases of ovarian cancer, 34 cases of hysteromyoma, 29 cases of benign teratoma), before and after treatment were examined by the method of enzyme-linked immunosorbent assay (ELISA) which were compared with standard serum level of CA125. Level above 35 kU/L was considered CA125 positive. Results CA125-positive rates in patients with ovarian cancer, hysteromyoma, benign teratoma and other benign gynecologic diseases were 94.7%(18/19), 17.6%(6/34), 24%(7/29) and 14.3%(6/42) respect-ively. Of the 19 ovarian cancer patients, serum CA125 lever of 15 cases decreased significantly (<35 kU/L) after chemical and surgical therapy. Conclusion Serum CA125 is reliable in the diagnosis, treatment evaluation and prognosis of ovarian cancer.
出处
《第一军医大学学报》
CSCD
2000年第3期252-253,共2页
Journal of First Military Medical University
